228 related articles for article (PubMed ID: 19015985)
1. Transmucosal gastric leak induced by proton pump inhibitors.
Murray LJ; Gabello M; Rudolph DS; Farrell CP; Morgan M; Martin AP; Underwood JC; Valenzano MC; Mullin JM
Dig Dis Sci; 2009 Jul; 54(7):1408-17. PubMed ID: 19015985
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole induces gastric transmucosal permeability to the peptide bradykinin.
Gabello M; Valenzano MC; Zurbach EP; Mullin JM
World J Gastroenterol; 2010 Mar; 16(9):1097-103. PubMed ID: 20205280
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole induces gastric permeability to digoxin.
Gabello M; Valenzano MC; Barr M; Zurbach P; Mullin JM
Dig Dis Sci; 2010 May; 55(5):1255-63. PubMed ID: 19513837
[TBL] [Abstract][Full Text] [Related]
4. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
5. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
6. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
8. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of the proton-pump inhibitors.
Reilly JP
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S11-7. PubMed ID: 10597119
[TBL] [Abstract][Full Text] [Related]
11. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.
Müller P; Göksu MA; Fuchs W; Schlüter F; Simon B
Aliment Pharmacol Ther; 2000 Sep; 14(9):1225-9. PubMed ID: 10971240
[TBL] [Abstract][Full Text] [Related]
12. The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.
Bastaki SM; Chandranath IS; Singh J
Mol Cell Biochem; 2008 Feb; 309(1-2):167-75. PubMed ID: 18044010
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
14. Association Between Proton Pump Inhibitors and Microscopic Colitis.
Law EH; Badowski M; Hung YT; Weems K; Sanchez A; Lee TA
Ann Pharmacother; 2017 Mar; 51(3):253-263. PubMed ID: 27733667
[TBL] [Abstract][Full Text] [Related]
15. Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.
Coruzzi G; Adami M; Bertaccini G
Gen Pharmacol; 1995 Sep; 26(5):1027-32. PubMed ID: 7557245
[TBL] [Abstract][Full Text] [Related]
16. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat.
Morini G; Grandi D; Arcari ML; Bertaccini G
Gen Pharmacol; 1995 Sep; 26(5):1021-5. PubMed ID: 7557244
[TBL] [Abstract][Full Text] [Related]
18. Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol.
Väkeväinen S; Tillonen J; Salaspuro M; Jousimies-Somer H; Nuutinen H; Färkkilä M
Aliment Pharmacol Ther; 2000 Nov; 14(11):1511-8. PubMed ID: 11069323
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase.
Mullin JM; Valenzano MC; Whitby M; Lurie D; Schmidt JD; Jain V; Tully O; Kearney K; Lazowick D; Mercogliano G; Thornton JJ
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1317-25. PubMed ID: 18684245
[TBL] [Abstract][Full Text] [Related]
20. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
